NASDAQ:AUPH Aurinia Pharmaceuticals (AUPH) Stock Price, News & Analysis → Never use this word on your phone (FBI could be watching) (From Paradigm Press) (Ad) Free AUPH Stock Alerts $5.10 -0.07 (-1.35%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$5.09▼$5.5550-Day Range$4.81▼$6.0252-Week Range$4.71▼$12.43Volume1.70 million shsAverage Volume1.38 million shsMarket Capitalization$729.40 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Aurinia Pharmaceuticals alerts: Email Address Aurinia Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside96.1% Upside$10.00 Price TargetShort InterestHealthy8.91% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.48Based on 11 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.06) to $0.55 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.47 out of 5 starsMedical Sector3883rd out of 5,424 stocksPharmaceutical Preparations Industry1795th out of 2,550 stocks 3.4 Analyst's Opinion Consensus RatingAurinia Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAurinia Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted8.91% of the float of Aurinia Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAurinia Pharmaceuticals has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Aurinia Pharmaceuticals has recently decreased by 6.94%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAurinia Pharmaceuticals does not currently pay a dividend.Dividend GrowthAurinia Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AUPH. Previous Next 1.9 News and Social Media Coverage News SentimentAurinia Pharmaceuticals has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Aurinia Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 14 people have searched for AUPH on MarketBeat in the last 30 days. This is a decrease of -42% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Aurinia Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aurinia Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.30% of the stock of Aurinia Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 36.83% of the stock of Aurinia Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aurinia Pharmaceuticals are expected to grow in the coming year, from ($0.06) to $0.55 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aurinia Pharmaceuticals is -11.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aurinia Pharmaceuticals is -11.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAurinia Pharmaceuticals has a P/B Ratio of 1.94. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad AltimetryUrgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.Click here to access… About Aurinia Pharmaceuticals Stock (NASDAQ:AUPH)Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Read More AUPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AUPH Stock News HeadlinesMay 2, 2024 | seekingalpha.comAurinia Pharmaceuticals Inc. (AUPH) Q1 2024 Earnings Call TranscriptMay 2, 2024 | markets.businessinsider.comLeerink Partners Keeps Their Buy Rating on Aurinia Pharmaceuticals (AUPH)May 4, 2024 | Paradigm Press (Ad)Never use this word on your phone (FBI could be watching)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...May 2, 2024 | businesswire.comAurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational ResultsMay 1, 2024 | markets.businessinsider.comAurinia Pharmaceuticals is about to announce earnings — here's what Wall Street expectsMay 1, 2024 | businesswire.comAurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness MonthApril 30, 2024 | seekingalpha.comAurinia: Updated Lupkynis Label Should Keep Sales Growth Momentum GoingApril 30, 2024 | businesswire.comThe U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical ProgramMay 4, 2024 | Paradigm Press (Ad)Never use this word on your phone (FBI could be watching)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...April 25, 2024 | americanbankingnews.comAurinia Pharmaceuticals (AUPH) Set to Announce Earnings on ThursdayApril 18, 2024 | seekingalpha.comAurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024April 16, 2024 | businesswire.comUPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceApril 15, 2024 | businesswire.comAurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024April 9, 2024 | businesswire.comAurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor ConferenceApril 9, 2024 | sg.finance.yahoo.comBRIEF-Soilbuild Construction Says Group Awarded New ContractsApril 7, 2024 | finance.yahoo.comWhen Will Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Breakeven?March 17, 2024 | finance.yahoo.com11 Oversold Biotech Stocks To Buy Right NowMarch 14, 2024 | finance.yahoo.comAUPH Mar 2024 3.000 callMarch 8, 2024 | finance.yahoo.comWe're Not Worried About Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash BurnMarch 5, 2024 | seekingalpha.comAurinia Pharma: Cheaper Now, But Buyout Hopes DashedMarch 1, 2024 | markets.businessinsider.comAurinia Pharmaceuticals: Strong Buy Rating Amidst Share Repurchase and Promising LUPKYNIS ProspectsFebruary 29, 2024 | finance.yahoo.comAurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase ProgramFebruary 28, 2024 | investing.comAurinia Pharmaceuticals Inc (AUPH)February 27, 2024 | businesswire.comAurinia to Participate in Upcoming Investor Healthcare ConferencesFebruary 26, 2024 | finance.yahoo.comAUPH Oct 2024 8.000 callFebruary 23, 2024 | finance.yahoo.comAUPH Jan 2025 15.000 callFebruary 23, 2024 | finance.yahoo.comAUPH Oct 2024 6.000 putSee More Headlines Receive AUPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/15/2024Today5/04/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AUPH CUSIPN/A CIK1600620 Webwww.auriniapharma.com Phone250-708-4272Fax250-744-2498Employees300Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$13.00 Low Stock Price Target$8.00 Potential Upside/Downside+96.1%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-78,020,000.00 Net Margins-44.45% Pretax Margin-44.14% Return on Equity-20.10% Return on Assets-14.84% Debt Debt-to-Equity Ratio0.20 Current Ratio5.50 Quick Ratio4.99 Sales & Book Value Annual Sales$175.51 million Price / Sales4.16 Cash FlowN/A Price / Cash FlowN/A Book Value$2.63 per share Price / Book1.94Miscellaneous Outstanding Shares143,019,000Free Float136,869,000Market Cap$729.40 million OptionableOptionable Beta1.36 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Peter S. Greenleaf M.B.A. (Age 54)President, CEO & Director Comp: $1.34MMr. Joseph M. Miller CPA (Age 50)Chief Financial Officer Comp: $791.92kMr. Matthew Maxwell Donley M.B.A. (Age 55)Executive Vice President of Operations & Strategy Comp: $811.82kMr. Stephen P. Robertson (Age 42)Executive VP, General Counsel, Corporate Secretary & Chief Compliance Officer Comp: $739.68kDr. Volker Knappertz D.Sc. (Age 59)M.D., Executive Vice President of Research & Development Comp: $742.85kAndrea Levin ChristopherHead of the Corporate Communications & Investor RelationsMr. Fran LynchVice President of SalesMr. Michael R. Martin (Age 52)Chief Business Officer Comp: $350.57kMs. Sue EvansSenior Vice President of Global Regulatory AffairsMr. Scott Habig (Age 64)Chief Commercial Officer More ExecutivesKey CompetitorsOcular TherapeutixNASDAQ:OCULPraxis Precision MedicinesNASDAQ:PRAXPureTech HealthNASDAQ:PRTCPliant TherapeuticsNASDAQ:PLRXLongboard PharmaceuticalsNASDAQ:LBPHView All CompetitorsInsiders & InstitutionsGSA Capital Partners LLPBought 231,260 shares on 5/3/2024Ownership: 0.244%Nordea Investment Management ABBought 105,100 shares on 5/2/2024Ownership: 0.216%Fifth Lane Capital LPSold 35,000 shares on 5/2/2024Ownership: 0.000%BNP Paribas Financial MarketsBought 8,398 shares on 5/1/2024Ownership: 0.054%Mirae Asset Global Investments Co. Ltd.Sold 4,170 shares on 5/1/2024Ownership: 0.041%View All Insider TransactionsView All Institutional Transactions AUPH Stock Analysis - Frequently Asked Questions Should I buy or sell Aurinia Pharmaceuticals stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AUPH shares. View AUPH analyst ratings or view top-rated stocks. What is Aurinia Pharmaceuticals' stock price target for 2024? 4 brokerages have issued 1-year price objectives for Aurinia Pharmaceuticals' shares. Their AUPH share price targets range from $8.00 to $13.00. On average, they expect the company's share price to reach $10.00 in the next year. This suggests a possible upside of 96.1% from the stock's current price. View analysts price targets for AUPH or view top-rated stocks among Wall Street analysts. How have AUPH shares performed in 2024? Aurinia Pharmaceuticals' stock was trading at $8.99 at the beginning of 2024. Since then, AUPH shares have decreased by 43.3% and is now trading at $5.10. View the best growth stocks for 2024 here. Are investors shorting Aurinia Pharmaceuticals? Aurinia Pharmaceuticals saw a drop in short interest during the month of April. As of April 15th, there was short interest totaling 11,390,000 shares, a drop of 6.9% from the March 31st total of 12,240,000 shares. Based on an average trading volume of 2,060,000 shares, the days-to-cover ratio is presently 5.5 days. Currently, 8.9% of the shares of the company are short sold. View Aurinia Pharmaceuticals' Short Interest. When is Aurinia Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our AUPH earnings forecast. How were Aurinia Pharmaceuticals' earnings last quarter? Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) released its quarterly earnings results on Thursday, February, 15th. The biotechnology company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by $0.03. The biotechnology company earned $45.10 million during the quarter, compared to analyst estimates of $45 million. Aurinia Pharmaceuticals had a negative trailing twelve-month return on equity of 14.79% and a negative net margin of 32.69%. The business's revenue was up 58.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.18) earnings per share. What ETF holds Aurinia Pharmaceuticals' stock? Virtus LifeSci Biotech Products ETF holds 42,195 shares of AUPH stock, representing 1.15% of its portfolio. What other stocks do shareholders of Aurinia Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), Exelixis (EXEL), AbbVie (ABBV), Amarin (AMRN) and Array Technologies (ARRY). Who are Aurinia Pharmaceuticals' major shareholders? Aurinia Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include GSA Capital Partners LLP (0.24%), Nordea Investment Management AB (0.22%), Simplex Trading LLC (0.00%), Sunbelt Securities Inc. (0.13%), BNP Paribas Financial Markets (0.05%) and Hennion & Walsh Asset Management Inc. (0.05%). Insiders that own company stock include David RW Jayne, George M Milne Jr, Jill Leversage, Joseph M Miller, Joseph P Hagan, Matthew Maxwell Donley, Michael Robert Martin, Neil Solomons, Peter Greenleaf, Robert Bindert Huizinga and Stephen P Robertson. View institutional ownership trends. How do I buy shares of Aurinia Pharmaceuticals? Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AUPH) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchForget Nvidia. This is the future of AIPorter & CompanyHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceThe asset beating inflation by 4xColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aurinia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
